Webinar Presents How to Reduce Risk of mAb Aggregation in Bioprocessing
Issue: February 17, 2017
| Categories: Downstream, Formulation, Merck topics, Regulatory Topics, Upstream
Please join us on March 23 for our new webinar, “Product Aggregation in Bioprocessing: Origins, Prevention, and Removal,” presented by Dr. Paul Beckett.
The tendency for most biological products to self-associate and aggregate, often irreversibly, is a considerable challenge in process management and design. Aggregated products lead to patient safety concerns, process challenges and lost yield. Therefore, it is important to reduce the aggregation of the biological product during processing and to remove aggregates efficiently and effectively.
Our webinar will explore how and why biological product aggregates form within a bioprocessing environment, based on process conditions and biochemistry, and how these are detected. Strategies for reducing the risk of aggregation are discussed at each stage of the process, and proven methods for removal of aggregates effectively are presented.
In This Same Issue